Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy

Author:

Lei Yaran12,Yang Yulu13,Yang Guobao1,Li Ao14,Yang Yang1,Wang Yuli1,Gao Chunsheng1

Affiliation:

1. State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China

2. School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Benxi 117004, China

3. School of Pharmacy, Guangxi Medical University, Nanning 530021, China

4. School of Pharmacy, Henan University, Kaifeng 475004, China

Abstract

Colchicine (COL), a widely used natural drug, has potent anti-inflammatory effects; however, as a narrow therapeutic index drug, its clinical application is limited by its serious gastrointestinal adverse effects, and only oral formulations are currently marketed worldwide. Recent studies have shown that transdermal, injection, and oral drug delivery are the three main delivery strategies for COL. This article elaborates on the research progress of different delivery strategies in terms of toxicity reduction and efficacy enhancement, depicting that the transdermal drug delivery route can avoid the first-pass effect and the traumatic pain associated with the oral and injection routes, respectively. Therefore, such a dosage form holds a significant promise that requires the development of further research to investigate effective COL delivery formulations. In addition, the permeation-promoting technologies utilized for transdermal drug delivery systems are briefly discussed. This article is expected to provide scientific ideas and theoretical guidance for future research and the exploration of COL delivery strategies.

Funder

National Science and Technology

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference111 articles.

1. Isolating Colchicine in 19th Century: An Old Drug Revisited;Karamanou;Curr. Pharm. Des.,2018

2. Colchicine in Cardiovascular Disease: In-Depth Review;Deftereos;Circulation,2022

3. Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease;Robinson;Am. J. Med.,2022

4. Repurposing Colchicine for Heart Disease;Bouabdallaoui;Annu. Rev. Pharmacol. Toxicol.,2022

5. Agepha Pharma US (2023, June 20). FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease. Available online: https://us.agephapharma.com/blog/2023/06/20/us-fda-approves-first-anti-inflammatory-drug-for-cardiovascular-disease/.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3